Notice of Award of a Sole Source Cooperative Agreement To Fund National Health Laboratory Service (NHLS), 19594 [2024-05777]
Download as PDF
<![CDATA[
19594
Federal Register / Vol. 89, No. 54 / Tuesday, March 19, 2024 / Notices
(STIs), viral hepatitis, and associated
chronic co-infections and
noncommunicable diseases (NCDs);
promote health equity; increase
sustainability of programs; strengthen
public health systems and health
security; and follow science.
WHO is in a unique position to
conduct this work, as it is the sole
international global health organization
responsible for issuing normative
standard and guidelines for
implementation of health programs
including HIV/AIDS within the UN
system. No other organization has the
authority to issue international
standards for health in the UN system
as denoted by the WHO constitution
signed in 1948.
Summary of the Award
Recipient: World Health Organization
(WHO).
Purpose of the Award: The purpose of
this award is to support the
development of global guidelines and
provide technical assistance through
WHO to aid PEPFAR-supported
countries to meet the 95–95–95 targets
and achieve program sustainability by
2030. In alignment with the 2022
PEPFAR Five-Year Strategy.
Amount of Award: For WHO, the
approximate year 1 funding amount will
be $20,000,000 in Federal Fiscal Year
(FYY) 2024 funds, subject to the
availability of funds. Funding amounts
for years 2–5 will be set at continuation.
Authority: This program is authorized
under Public Law 108–25 (the United
States Leadership Against HIV AIDS,
Tuberculosis and Malaria Act of 2003)
(22 U.S.C. 7601, et seq.) and Public Law
110–293 (the Tom Lantos and Henry J.
Hyde United States Global Leadership
Against HIV/AIDS, Tuberculosis, and
Malaria Reauthorization Act of 2008),
and Public Law 113–56 (PEPFAR
Stewardship and Oversight Act of 2013).
Additionally, this program is authorized
under section 307 of the Public Health
Service Act (42 U.S.C. 242l), as
amended and section 301(a) of the
Public Health Service Act (42 U.S.C.
241(a)), as amended.
ddrumheller on DSK120RN23PROD with NOTICES1
Non-PEPFAR Funding
Additionally, this program is
authorized under the Public Health
Service Act 42 CFR part 51b—Project
Grants for Preventive Health Services
section 318 (42 U.S.C. 247c) section 318
(42 U.S.C. 247c) Sexually transmitted
diseases; prevention and control
projects; sections 301(a), 317N, and 318
of the Public Health Service Act (42
U.S.C. 241(a), 247b–15, and 247c).
VerDate Sep<11>2014
17:41 Mar 18, 2024
Jkt 262001
Period of Performance: The period for
this award will be September 30, 2024,
through September 29, 2029.
Dated: March 13, 2024.
Jamie Legier,
Acting Director, Office of Grants Services,
Centers for Disease Control and Prevention.
[FR Doc. 2024–05774 Filed 3–18–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Award of a Sole Source
Cooperative Agreement To Fund
National Health Laboratory Service
(NHLS)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), located
within the Department of Health and
Human Services (HHS), announces the
award(s) of approximately $5,000,000,
for Year 1 funding to NHLS. The(se)
award(s) will strengthen laboratory
systems for improved access to
sustainable delivery of quality
laboratory services and promote rational
use of diagnostic services in South
Africa through above site interventions.
Funding amounts for years 2–5 will be
set at continuation.
DATES: The period for this award will be
September 30, 2024, through September
29, 2029.
FOR FURTHER INFORMATION CONTACT:
Artur Ramos, Center for Global Health,
Centers for Disease Control and
Prevention, 100 Totius Street,
Groenkloof, Pretoria, telephone:
3108483712, e-Mail: cer9@cdc.gov.
SUPPLEMENTARY INFORMATION: The(se)
sole source award(s) will address gaps
in line with PEPFAR strategies and the
Government of South Africa’s key
priority areas that need continued
PEPFAR support. This includes
developing and reviewing laboratory
policies, strategic plans, and governance
structures to expand diagnostic health
equity and response to Human
Immunodeficiency Virus (HIV),
Tuberculosis (TB) and related public
health needs. It also includes
prioritizing technical and systems
advancements to increase operational
efficiencies and improve service
delivery as well as supporting an
environment that facilitates and
endorses integration, ownership, and
SUMMARY:
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
sustainable transition of PEPFARfunded laboratory activities to NHLS
and the National Department of Health.
NHLS is in a unique position to
conduct this work, as it is the sole
provider of diagnostic pathology
services to the public sector in South
Africa and has been mandated by the
government of South Africa under the
National Health Laboratory Service Act,
2000 to provide quality, affordable, and
sustainable laboratory and related
public health services. Quality
laboratory testing is an essential
building block of the HIV clinical
cascade as accurate and timely clinical
laboratory services will facilitate the
earlier diagnosis of HIV, staging,
identification of adverse drug events
and opportunistic infections, and
monitoring the response of individual
patients to therapy, including
identification of treatment failures.
Summary of the Award
Recipient: National Health Laboratory
Service (NHLS).
Purpose of the Award: The purpose of
this award is to strengthen laboratory
systems for improved access to
sustainable delivery of quality
laboratory services and promote rational
use of diagnostic services in South
Africa through above site interventions.
Amount of Award: For NHLS, the
approximate year 1 funding amount will
be $5,000,000 in Federal Fiscal Year
(FYY) 2024 funds, subject to the
availability of funds. Funding amounts
for years 2–5 will be set at continuation.
Authority: This program is authorized
under Public Law 108–25 (the United
States Leadership Against HIV AIDS,
Tuberculosis and Malaria Act of 2003)
(22 U.S.C. 7601, et seq.) and Public Law
110–293 (the Tom Lantos and Henry J.
Hyde United States Global Leadership
Against HIV/AIDS, Tuberculosis, and
Malaria Reauthorization Act of 2008),
and Public Law 113–56 (PEPFAR
Stewardship and Oversight Act of 2013).
Additionally, this program is authorized
under section 307 of the Public Health
Service Act (42 U.S.C. 242l), as
amended and section 301(a) of the
Public Health Service Act (42 U.S.C.
241(a)), as amended.
Period of Performance: The period for
this award will be September 30, 2024,
through September 29, 2029.
Dated: March 13, 2024.
Jamie Legier
Acting Director, Office of Grants Services,
Centers for Disease Control and Prevention.
[FR Doc. 2024–05777 Filed 3–18–24; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\19MRN1.SGM
19MRN1
]]>Agencies
[Federal Register Volume 89, Number 54 (Tuesday, March 19, 2024)]
[Notices]
[Page 19594]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-05777]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Award of a Sole Source Cooperative Agreement To Fund
National Health Laboratory Service (NHLS)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC), located
within the Department of Health and Human Services (HHS), announces the
award(s) of approximately $5,000,000, for Year 1 funding to NHLS.
The(se) award(s) will strengthen laboratory systems for improved access
to sustainable delivery of quality laboratory services and promote
rational use of diagnostic services in South Africa through above site
interventions. Funding amounts for years 2-5 will be set at
continuation.
DATES: The period for this award will be September 30, 2024, through
September 29, 2029.
FOR FURTHER INFORMATION CONTACT: Artur Ramos, Center for Global Health,
Centers for Disease Control and Prevention, 100 Totius Street,
Groenkloof, Pretoria, telephone: 3108483712, e-Mail: [email protected].
SUPPLEMENTARY INFORMATION: The(se) sole source award(s) will address
gaps in line with PEPFAR strategies and the Government of South
Africa's key priority areas that need continued PEPFAR support. This
includes developing and reviewing laboratory policies, strategic plans,
and governance structures to expand diagnostic health equity and
response to Human Immunodeficiency Virus (HIV), Tuberculosis (TB) and
related public health needs. It also includes prioritizing technical
and systems advancements to increase operational efficiencies and
improve service delivery as well as supporting an environment that
facilitates and endorses integration, ownership, and sustainable
transition of PEPFAR-funded laboratory activities to NHLS and the
National Department of Health.
NHLS is in a unique position to conduct this work, as it is the
sole provider of diagnostic pathology services to the public sector in
South Africa and has been mandated by the government of South Africa
under the National Health Laboratory Service Act, 2000 to provide
quality, affordable, and sustainable laboratory and related public
health services. Quality laboratory testing is an essential building
block of the HIV clinical cascade as accurate and timely clinical
laboratory services will facilitate the earlier diagnosis of HIV,
staging, identification of adverse drug events and opportunistic
infections, and monitoring the response of individual patients to
therapy, including identification of treatment failures.
Summary of the Award
Recipient: National Health Laboratory Service (NHLS).
Purpose of the Award: The purpose of this award is to strengthen
laboratory systems for improved access to sustainable delivery of
quality laboratory services and promote rational use of diagnostic
services in South Africa through above site interventions.
Amount of Award: For NHLS, the approximate year 1 funding amount
will be $5,000,000 in Federal Fiscal Year (FYY) 2024 funds, subject to
the availability of funds. Funding amounts for years 2-5 will be set at
continuation.
Authority: This program is authorized under Public Law 108-25 (the
United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act
of 2003) (22 U.S.C. 7601, et seq.) and Public Law 110-293 (the Tom
Lantos and Henry J. Hyde United States Global Leadership Against HIV/
AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008), and
Public Law 113-56 (PEPFAR Stewardship and Oversight Act of 2013).
Additionally, this program is authorized under section 307 of the
Public Health Service Act (42 U.S.C. 242l), as amended and section
301(a) of the Public Health Service Act (42 U.S.C. 241(a)), as amended.
Period of Performance: The period for this award will be September
30, 2024, through September 29, 2029.
Dated: March 13, 2024.
Jamie Legier
Acting Director, Office of Grants Services, Centers for Disease Control
and Prevention.
[FR Doc. 2024-05777 Filed 3-18-24; 8:45 am]
BILLING CODE 4163-18-P
